Drug Trial Radar · NCT06610266
Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 28, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Yongquan ShiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.
Conditions
- Gastric Intestinal Metaplasia
Interventions
WeifuchunDrug
Subjects will be instructed to take four tablets (1400mg) of Weifuchun three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
Folic AcidDrug
Subjects will be instructed to take one tablet (5mg) of folic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The regression rate of gastric intestinal metaplasia based on OLGIM stage in different groups.Time frame: From enrollment to the end of treatment at 6 months.
- The progression rate of gastric intestinal metaplasia based on OLGIM stage in different groups.Time frame: From enrollment to the end of treatment at 6 months.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Ankang Central Hospital
Ankang, China · Recruiting
Tongchuan People's Hospital
Tongchuan, China · Recruiting
Weinan Central Hospital
Weinan, China · Recruiting
The 986th Hospital of Air Force Medical University
Xi'an, China · Recruiting
Xijing hospital
Xi'an, China · Recruiting
Xi'an Central Hospital
Xi'an, China · Recruiting
Xi'an Honghui Hospital
Xi'an, China · Recruiting
Xunyang People's Hospital
Xuchang, China · Recruiting
Affiliated Hospital of Yan'an University
Yanan, China · Recruiting
Shangluo Central Hospital
Shangluo, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.